Gilead Sciences | GILD - Interest Expense On Debt

Stock Price
130.40
Daily Change
-3.24 -2.42%
Monthly
-5.68%
Yearly
26.39%
Q2 Forecast
127.61

Gilead Sciences reported $255M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
AbbVie USD 740M 40M Jun/2025
Agios Pharmaceuticals USD 1.39B 85.53M Sep/2025
ALKERMES USD 12.28M 7.63M Dec/2025
Alnylam Pharmaceuticals USD 129.34M 84.94M Dec/2025
Amgen USD 653M 32M Dec/2025
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 2.78M 199K Dec/2025
Bristol-Myers Squibb USD 432M 48M Dec/2025
Coherus Biosciences USD 2.25M 76K Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Gilead Sciences USD 255M 1000K Dec/2025
GlaxoSmithKline GBP 188M 21M Dec/2025
Glaxosmithkline GBP 177.95M 6.05M Sep/2025
Incyte USD 582K 10K Dec/2025
J&J USD 43M 25M Mar/2026
Merck USD 412M 85M Dec/2025
Moderna USD 12.14B 12.13B Sep/2025
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novartis USD 304M 23M Dec/2025
Pfizer USD 711M 59M Dec/2025
PTC Therapeutics USD 50.58M 2.59B Dec/2025
Puma Biotechnology USD 3.37M 11K Jun/2024
Regeneron Pharmaceuticals USD 12.2M 7.1M Dec/2025
Sangamo BioSciences 97.56M 11.39M Jun/2025
Sanofi EUR 178M 203M Mar/2026
Sarepta Therapeutics USD 7.56M 2.33M Sep/2025
United Therapeutics USD 3.1M 100K Dec/2025
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025